1. Medtech Insight
  2. >>Policy & Regulation

FDA Eyes Upclassification, Labeling Guidance To Address Stapler Risks

 
• By David Filmore

The US agency sent a letter to health-care providers spotlighting its analysis of the increasing numbers of adverse events linked to surgical staplers and implantable staples, and its plans for a draft guidance on labeling and an advisory panel meeting to consider a 510(k) requirement for the products.

Surgical Staple Instruments

Surgical staplers and staple manufacturers have a draft guidance and reclassification advisory committee meeting to look forward to in 2019 as US FDA takes a closer look at the high volume of adverse event reports that have flowed in for the devices.

The agency circulated a letter to health-care providers March 8 highlighting safety concerns based on FDA's analysis of submitted Medical Device Reports

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation